Boston Scientific Shoots For Cardiac Ablation Leadership With $387M Farapulse Acquisition

Boston Scientific will exercise its option to buy the remaining 73% of Farapulse, the first company to market a pulsed field cardiac ablation system.

Farapulse, Inc.’s Farawave PFA catheter
Farapulse's Farawave PFA Catheter • Source: Farapulse

Boston Scientific’s full acquisition of Farapulse affirms its confidence that pulsed field ablation (PFA) technology can accelerate the growth of its electrophysiology business.

Boston Scientific first invested in Farapulse in 2014 and currently owns 27% of the Menlo Park, CA-based company. Mary Byron,...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Deals

More from Business